文献速递消化道肿瘤放疗放疗物理与技术

食管癌新辅助放化疗期间严重淋巴细胞减少:质子与光子放疗相对风险的倾向匹配分析

Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
PubMed 文献 · Radiother Oncol · 2017-12-14

该研究比较了食管癌新辅助放化疗中调强放疗(IMRT)与质子束治疗(PBT)引起4级淋巴细胞减少的相对风险。倾向匹配后,IMRT组4级淋巴细胞减少发生率为40.4%,PBT组为17.6%(P<0.0001),多因素分析显示PBT显著降低4级淋巴细胞减少风险(OR 0.29,95%CI 0.16-0.52,P<0.0001)。

要点

  • PBT组4级淋巴细胞减少发生率显著低于IMRT组(17.6% vs 40.4%,P<0.0001)。
  • 多因素分析显示PBT与4级淋巴细胞减少风险降低独立相关(OR 0.29,95%CI 0.16-0.52)。
  • 食管癌新辅助放化疗中,质子治疗可能减少严重淋巴细胞减少。

核心结论

  • PBT与食管癌新辅助放化疗期间4级淋巴细胞减少风险显著降低相关。

研究设计与样本

  • 回顾性队列研究,纳入480例接受新辅助放化疗的食管癌患者,按关键临床变量进行倾向评分匹配,最终匹配136例IMRT与136例PBT患者。
  • 治疗相关淋巴细胞减少采用CTCAE v4.0分级,使用单因素和多因素logistic回归分析相关因素。

主要发现

  • 匹配队列中,IMRT组55/136(40.4%)发生4级淋巴细胞减少,PBT组24/136(17.6%)发生,差异显著(P<0.0001)。
  • 多因素分析中,PBT与4级淋巴细胞减少风险降低显著相关(OR 0.29,95%CI 0.16-0.52,P<0.0001)。

临床怎么用

  • 对于接受新辅助放化疗的食管癌患者,选择质子束治疗可能有助于降低严重淋巴细胞减少的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Circulating lymphocytes are exquisitely sensitive to radiation exposure, even to low scattered doses which can vary drastically between radiation modalities. We compared the relative risk of radiation-induced lymphopenia between intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT) in esophageal cancer (EC) patients undergoing neoadjuvant chemoradiation therapy (nCRT). MATERIAL AND METHODS: EC patients treated with IMRT and PBT were propensity matched based on key clinical variables. Treatment-associated lymphopenia was graded using CTCAE v.4.0. Using matched cohorts, univariate and multivariable multiple logistic regression was used to identify factors associated with increased risk of grade 4 lymphopenia as well as characterize their relative contributions. RESULTS: Among the 480 patients treated with nCRT, 136 IMRT patients were propensity score matched with 136 PBT patients. In the matched groups, a greater proportion of the IMRT patients (55/136, 40.4%) developed grade 4 lymphopenia during nCRT compared with the PBT patients (24/136, 17.6%, P < 0.0001). On multivariable analysis, PBT was significantly associated with a reduction in grade 4 lymphopenia risk (odds ratio, 0.29; 95% confidence interval, 0.16-0.52; P < 0.0001). CONCLUSION: PBT is associated with significant risk reduction in grade 4 lymphopenia during nCRT in esophageal cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2017. PMID: 29248170. doi:10.1016/j.radonc.2017.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。